Urinary pH opens a new paradigm in the control and prevention of lithiasis

The main specialists of urology in Spain, meeting in A Coruña on 26 and 27 January, highlight for the first time the emerging importance of urinary pH in the control and management of lithiasis and other pathologies

10% of the Spanish population is affected by chronic lithiasis, one of the main urological diseases

Devicare's new Lit-Control® pH Meter and its range of food supplements have been introduced as an innovative and effective medical solution to control urinary pH

Cerdanyola del Vallès (Barcelona), 1st February 2017 – The importance of monitoring urinary pH, the prevention of catheter encrustations, and the introduction of the use of new, effective medical solutions such as Lit-Control® to prevent urological pathologies, primarily lithiasis, are the major issues put on the table by the specialists during the XXVII National Meeting of the Groups of Lithiasis, Endourology, Laparoscopy and Robotics of the Spanish Association of Urology, held the 26th and 27th January in A Coruña (Spain). Among them, Prof Olivier Traxer from the University of Paris, one of the world's key opinion leaders in this field.

“Urinary pH can induce the direct formation of uric acid calculi (pH <5.5) or calcium phosphate calculi (pH >6.2), that is, lithiasis” remarked Prof Félix Grases, chair professor at the University of the Balearic Islands. Currently in Spain renal and urinary lithiasis (stones in the kidneys, ureters, bladder, or urethra) affects 10% of the population, mostly men, besides the 325,000 new cases that are diagnosed every year according to data from the Ministry of Health. Lithiasis appears on the list of high-prevalence chronic diseases of the EU.

During the medical scientific meeting, Prof Grases presented Lit-Control® pH Meter, the new first-in-class device developed and manufactured by Devicare, as the best solution “that allows an accurate and immediate measurement of urinary pH with freshly obtained urine compared to that performed with a laboratory pH meter”.

Dr Sergi Colom from the Bellvitge University Hospital highlighted the importance of
monitoring urinary pH in order to "**prevent the encrustation of the catheters through the acidification with L-methionine and phytin**". And this can already be managed thanks to the new **food supplement** Lit-Control® pH Down by Devicare, with patented formulation, available in the Spanish pharmacies since 2016.

"Diet also influences the formation of stones”, explained **Dr Carlos Reina** from the Hospital of Valme, in Sevilla, while **Dr Juan Alberto Lancina** from the University Hospital Complex A Coruña talked about metabolic syndrome, which affects 25% of the Spanish population, as “another risk factor for urinary lithiasis”.

**Lit-Control® for recurrent urinary diseases**

Devicare has been a **pioneer in developing a domiciliary method for the self-management** of frequent urological pathologies called **Lit-Control®**. This method is made up by the Lit-Control® pH Meter medical device and the Lit-Control® pH Up and Lit-Control® pH Down food supplements.

The benefits for the patients are that they can monitor and control urinary pH in an easy, quick, convenient, and reliable way, which helps prevent the formation of kidney stones and avoid the recurrence of the infection, among other advantages; and for the physicians, a better follow-up of the patients and a greater adherence to and effectiveness of the treatment.

In Spain, Lit Control® is marketed through **M4 Pharma** and in Mexico with **InnovaSalud**. In 2017 Devicare expects to introduce it in other countries in Europe and Latin America.

**About Devicare**

**Devicare** is a company specialized in the development, manufacture and remote management of innovative medical devices for the home care of chronic patients. These solutions are developed under the concept of **connected self-testing medical devices** in order to enable the patient to actively participate in the monitoring of their disease with the use of the devices. The placing on the market of these products is carried out through agreements with pharmaceutical companies.

Devicare's headquarters is located at the UAB Research Park, in Cerdanyola del Vallès, near Barcelona (Spain). In 2016, the company expects revenues of 500,000 euros. Since its foundation, Devicare has raised about 3 million euros in investment capital. The last round has been completed partially this 2016 with an amount of €850,000, leaded by the holding EMESA Corporación Empresarial (corporation of Emilio Cuatrecasas), but it remains open to incorporate new investors into the project.

-----

**Further information:**

**Devicare**
Gemma Escarré (Head of Communications)
T. 667 76 15 24 - gescarre@devicare.com